Seorin Bio, COVID-19 (Plasma Therapy/Plasma Therapeutics) Theme Rises 7.83% Up

On the 29th, the COVID-19 (plasma treatment/plasma therapy) theme showed strength by rising 3.02% compared to the previous day, with Seorin Bio, a related stock drawing attention, soaring 7.83% from the previous day. Seorin Bio is known as a bio-infrastructure specialized company.

[Graph] Major stock price changes in the COVID-19 (plasma treatment/plasma therapy) theme

According to provisional data compiled at 14:26, foreign investors have been making large net purchases of Seorin Bio, buying 17,700 shares.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)

According to the analysis by Thinkpool Robo Algorithm RASSI, Seorin Bio ranked 2nd out of 9 stocks in the quant financial ranking by exceeding the theme’s average scores in growth, stability, and profitability. This can be interpreted as Seorin Bio having relatively high investment attractiveness compared to other stocks within the theme from a financial perspective.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the Robo Algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, and other factors.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.